The prognostic role of polypharmacy in metastatic colorectal cancer patients treated with regorafenib.

Aim: To evaluate polypharmacy (PP) in patients with metastatic colorectal cancer receiving regorafenib. Methods: Patients with metastatic colorectal cancer receiving regorafenib were included and divided into two categories by their PP status: PP - (<5 regular drug use/day) and PP + (≥5 regular drug use/day). Results: 80 patients were included. 31 (38.7%) patients had PP. The median number of drugs used was three and seven in PP -  and PP + patients, respectively. Antiemetics (26.5%) and antacids (48.4%) were the most common drugs used by PP - and PP + patients, respectively. In multivariate analysis, the risk of death was higher in PP + patients (hazard ratio: 2.1; 95% CI: 1.2-3.7; p = 0.005). Conclusion: PP was an independent prognostic factor for overall survival in patients with metastatic colorectal cancer receiving regorafenib.